DOSE OF REALITY: BIG PHARMA TAX AVOIDANCE PRACTICES COME UNDER SCRUTINY IN SENATE FINANCE HEARING
May 12, 2023
Report Finds Big Pharma Games the System to Avoid Paying U.S. Taxes While… Read More
© 2024 CSRXP- All Rights Reserved
Dose of Reality
DOSE OF REALITY: SENATORS MUST HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS INSULIN PRICING PRACTICES
May 9, 2023
Lawmakers Have Opportunity to Grill Big Pharma Executives on Tactics Like… Read More
DOSE OF REALITY: LIST PRICE TRANSPARENCY WILL HELP HOLD BIG PHARMA ACCOUNTABLE AND LOWER PRESCRIPTION DRUG PRICES FOR PATIENTS
Apr 25, 2023
Congress Should Advance Bipartisan, Market-Based Measures to Increase… Read More
DOSE OF REALITY: EXPERT ASSESSMENT CONFIRMS BIG PHARMA’S PRICING OF NEW ALZHEIMER’S TREATMENT EXCEEDS FAIR PRICE
Apr 18, 2023
ICER Analysis of Leqembi Finds $26,500 Price Tag Exceeds Drug’s “Cost… Read More
DOSE OF REALITY: LAWMAKERS GET CHANCE TO HOLD BIG PHARMA ACCOUNTABLE FOR COVID-19 PRICE-GOUGING AHEAD OF COMMERCIAL DISTRIBUTION
Mar 20, 2023
Senate HELP Committee to Question Moderna CEO on Nearly 500 Percent Price Hike… Read More
DOSE OF REALITY: BIG PHARMA IS THE CULPRIT BEHIND OUT-OF-CONTROL PRESCRIPTION DRUG PRICES
Feb 16, 2023
Lawmakers Should Focus Attention on Brand Name Drug Companies That Set Prices,… Read More
DOSE OF REALITY: SENATE HEARING PROVIDES OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS PATENT ABUSE
Feb 2, 2023
Critical Legislation Targets Anti-Competitive Practices like Patent Thickets… Read More
DOSE OF REALITY: BIG PHARMA’S PATENT THICKETS COST PATIENTS AND TAXPAYERS BILLIONS IN LOST SAVINGS EACH YEAR
Jan 26, 2023
New Matrix Global Advisors Report Shines Light on Cost of Big Pharma’s… Read More
DOSE OF REALITY: BREAKING DOWN BIG PHARMA’S YEAR OF BAD BEHAVIOR IN 2022
Dec 28, 2022
Get the Facts on Big Pharma’s Year of Out-of-Control Launch Prices… Read More
DOSE OF REALITY: NEW STUDY UNDERSCORES BIG PHARMA’S PRICING PRACTICES ARE ABOUT PROFITS, NOT VALUE FOR PATIENTS
Nov 1, 2022
JAMA Analysis Finds No Correlation Between Cancer Drug Prices and… Read More
DOSE OF REALITY: NEW STUDY DEBUNKS BIG PHARMA CLAIMS THAT HIGH PRESCRIPTION DRUG PRICES ARE TIED TO R&D INVESTMENTS
Sep 29, 2022
JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s… Read More
DOSE OF REALITY: BIG PHARMA’S PRICING PRACTICES DRIVE CRISIS OF AFFORDABILITY FOR CANCER PATIENTS
Sep 20, 2022
Shining a Light on How Big Pharma is Rapidly Increasing Prices on Oncology… Read More